Clinical Trial Update: Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing mometasone furoate 0.1% to Eucerin for skin toxicities in breast cancer patients receiving postmastectomy radiation; study completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Invasive Breast Cancer

Drugs mentioned

• Eucerin
• Mometasone Furoate 0.1% (mometasone furoate)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Invasive Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2019-10-03